Key result
Single 150 or 200 mg doses of dipyridamole significantly inhibited platelet aggregation at 1 hour, but multiple doses (150/200 mg twice daily for 11 days) had no detectable effect.
Why the study?
Does dipyridamole inhibit platelet aggregation and alter platelet cyclic AMP or thromboxane formation in normal subjects?
Population
18 normal subjects (12 given 150 or 200 mg tablets, 6 given 25, 50, and 100 mg tablets)
Design
Other
Follow-up
11 days
Authors
Loading...
Transient single-dose inhibition without sustained effect after repeated dosing; leaves open optimal regimens and relevance in patients.
Does dipyridamole inhibit platelet aggregation and alter platelet cyclic AMP or thromboxane formation in normal subjects?
Dipyridamole transiently inhibits platelet aggregation only at high single doses, with no sustained effect after multiple doses and no effect on cyclic AMP or thromboxane formation.
Gregov et al. (1987) studied Healthy volunteers (n=18). Dipyridamole was evaluated on Platelet aggregation in response to ADP and collagen. Single 150 or 200 mg doses of dipyridamole significantly inhibited platelet aggregation at 1 hour, but multiple doses (150/200 mg twice daily for 11 days) had no detectable effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: